



Supplementary Figure 1. Patient disposition. EOT, end of treatment.



Supplementary Figure 2: Effect of treatment on dysphagia. BET1, effervescent tablets for orodispersible use 2 x 1 mg/d; BET2, effervescent tablets for orodispersible use 2 x 2 mg/d ;BVS, budesonide viscous suspension 2 x 5ml [0.4 mg/ml]/d; EOT, end of treatment; PLA, placebo



Supplementary Figure 3: Effect of treatment on serum cortisol levels. BET1, effervescent tablets for orodispersible use 2 x 1 mg/d; BET2, effervescent tablets for orodispersible use 2 x 2 mg/d ; BVS, budesonide viscous suspension 2 x 5ml [0.4 mg/ml]/d; EOT, end of treatment; LLN, lower limit of normal; PLA, placebo

